124 related articles for article (PubMed ID: 27873692)
1. Assessment of the in vitro synergy of daptomycin plus linezolid against multidrug-resistant enterococci.
Entenza JM; Giddey M; Vouillamoz J; Moreillon P; Mancini S
J Glob Antimicrob Resist; 2014 Dec; 2(4):306-308. PubMed ID: 27873692
[TBL] [Abstract][Full Text] [Related]
2. β-Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium.
Smith JR; Barber KE; Raut A; Aboutaleb M; Sakoulas G; Rybak MJ
J Antimicrob Chemother; 2015; 70(6):1738-43. PubMed ID: 25645208
[TBL] [Abstract][Full Text] [Related]
3. In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.
Jevitt LA; Smith AJ; Williams PP; Raney PM; McGowan JE; Tenover FC
Microb Drug Resist; 2003; 9(4):389-93. PubMed ID: 15000746
[TBL] [Abstract][Full Text] [Related]
4. In Vitro Synergy of Telavancin and Rifampin Against Enterococcus faecium Resistant to Both Linezolid and Vancomycin.
Pankey GA; Ashcraft DS
Ochsner J; 2013; 13(1):61-5. PubMed ID: 23532828
[TBL] [Abstract][Full Text] [Related]
5. In vitro synergy of daptomycin plus rifampin against Enterococcus faecium resistant to both linezolid and vancomycin.
Pankey G; Ashcraft D; Patel N
Antimicrob Agents Chemother; 2005 Dec; 49(12):5166-8. PubMed ID: 16304195
[TBL] [Abstract][Full Text] [Related]
6. Biofilm Time-Kill Curves to Assess the Bactericidal Activity of Daptomycin Combinations against Biofilm-Producing Vancomycin-Resistant
Barber KE; Shammout Z; Smith JR; Kebriaei R; Morrisette T; Rybak MJ
Antibiotics (Basel); 2021 Jul; 10(8):. PubMed ID: 34438947
[TBL] [Abstract][Full Text] [Related]
7. Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
Smith JR; Yim J; Raut A; Rybak MJ
Antimicrob Agents Chemother; 2016 Apr; 60(4):2352-8. PubMed ID: 26833159
[TBL] [Abstract][Full Text] [Related]
8. β-Lactams enhance daptomycin activity against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium in in vitro pharmacokinetic/pharmacodynamic models.
Smith JR; Barber KE; Raut A; Rybak MJ
Antimicrob Agents Chemother; 2015 May; 59(5):2842-8. PubMed ID: 25753639
[TBL] [Abstract][Full Text] [Related]
9. Comparison of in vitro inhibitory and bactericidal activities of daptomycin (LY 146032) and four reference antibiotics, singly and in combination, against gentamicin-susceptible and high-level-gentamicin-resistant enterococci.
Louie A; Baltch AL; Ritz WJ; Smith RP; Asperilla M
Chemotherapy; 1993; 39(5):302-9. PubMed ID: 8396526
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of daptomycin versus linezolid and vancomycin against gram-positive uropathogens and ampicillin against enterococci, causing complicated urinary tract infections.
Wagenlehner FM; Lehn N; Witte W; Naber KG
Chemotherapy; 2005 May; 51(2-3):64-9. PubMed ID: 15870498
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacies of daptomycin, vancomycin, and linezolid in experimental enterococcal peritonitis.
Kajihara T; Nakamura S; Iwanaga N; Oshima K; Hirano K; Miyazaki T; Izumikawa K; Yanagihara K; Miyazaki Y; Hattori N; Kohno N; Kohno S; Mukae H
J Infect Chemother; 2017 Jul; 23(7):498-501. PubMed ID: 28108098
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant enterococci in an in vitro pharmacokinetic/pharmacodynamic simulated endocardial vegetation model.
Hall Snyder A; Werth BJ; Barber KE; Sakoulas G; Rybak MJ
J Antimicrob Chemother; 2014 Aug; 69(8):2148-54. PubMed ID: 24777900
[TBL] [Abstract][Full Text] [Related]
13. Time-kill study and synergistic activity of cell-wall inhibitor antibiotics in combination with gentamicin against Enterococcus faecalis and Enterococcus faecium.
Aligholi M; Emaneini M; Taherikalani M; Shahsavan S; Jabalameli F; Asadollahi P; Khoramian B; Eslampour MA
Acta Microbiol Immunol Hung; 2011 Sep; 58(3):219-26. PubMed ID: 21983323
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of rifampicin combination therapy for the treatment of enterococcal infections assessed in vivo using a Galleria mellonella infection model.
Skinner K; Sandoe JAT; Rajendran R; Ramage G; Lang S
Int J Antimicrob Agents; 2017 Apr; 49(4):507-511. PubMed ID: 28235571
[TBL] [Abstract][Full Text] [Related]
15. Colistin/daptomycin: an unconventional antimicrobial combination synergistic in vitro against multidrug-resistant Acinetobacter baumannii.
Galani I; Orlandou K; Moraitou H; Petrikkos G; Souli M
Int J Antimicrob Agents; 2014 Apr; 43(4):370-4. PubMed ID: 24560919
[TBL] [Abstract][Full Text] [Related]
16. Ceftobiprole and ampicillin increase daptomycin susceptibility of daptomycin-susceptible and -resistant VRE.
Werth BJ; Barber KE; Tran N; Nonejuie P; Sakoulas G; Pogliano J; Rybak MJ
J Antimicrob Chemother; 2015 Feb; 70(2):489-93. PubMed ID: 25304643
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial activity of linezolid combined with minocycline against vancomycin-resistant Enterococci.
Wu J; Jiang TT; Su JR; Li L
Chin Med J (Engl); 2013 Jul; 126(14):2670-5. PubMed ID: 23876894
[TBL] [Abstract][Full Text] [Related]
18. The Global Prevalence of Daptomycin, Tigecycline, and Linezolid-Resistant
Dadashi M; Sharifian P; Bostanshirin N; Hajikhani B; Bostanghadiri N; Khosravi-Dehaghi N; van Belkum A; Darban-Sarokhalil D
Front Med (Lausanne); 2021; 8():720647. PubMed ID: 34568377
[No Abstract] [Full Text] [Related]
19. The bactericidal activity of ampicillin, daptomycin, and vancomycin against ampicillin-resistant Enterococcus faecium.
el-Mady A; Mortensen JE
Diagn Microbiol Infect Dis; 1991; 14(2):141-5. PubMed ID: 1651825
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
